FHH45213
Human
Human
IgG1, kappa
Monoclonal
APC
MICA, MIC-A, MHC class I polypeptide-related sequence A, PERB11.1
0.5 mg/ml
Please contact with the lab for this information.
FCM
Liquid
0.01M PBS, pH 7.4, 0.2% BSA, 0.05% Proclin 300.
Store at 4°C for 12 months. Protect from light. Do not freeze.
16A8
Two major human phenotypes of MICA molecules and their differential activation to NK cells via NKG2D receptor., PMID:40458406
Insights into pathophysiology, biomarkers, and therapeutics in tauopathies: Proceedings of the Tau2024 Global Conference., PMID:40437880
NKG2D triggering hampers DNAM-1-mediated signaling in human NK cells., PMID:40421025
Insights into pathophysiology, biomarkers, and therapeutics in tauopathies: Proceedings of the Tau2024 Global Conference., PMID:40437880
Rationale and feasibility of a rapid integral biomarker program that informs immune-oncology clinical trials: the ADVISE trial., PMID:40389374
Rationale and feasibility of a rapid integral biomarker program that informs immune-oncology clinical trials: the ADVISE trial., PMID:40389374
Protocol for in-plate staining of clinical peripheral blood mononuclear cell samples for high-throughput analysis via spectral flow cytometry., PMID:40347474
Protocol for in-plate staining of clinical peripheral blood mononuclear cell samples for high-throughput analysis via spectral flow cytometry., PMID:40347474
Multiplex immunophenotyping of human acute myeloid leukemia patients revealed single -cell heterogeneity with special attention on therapy sensitive and therapy resistant subpopulations., PMID:40313947
Multiplex immunophenotyping of human acute myeloid leukemia patients revealed single -cell heterogeneity with special attention on therapy sensitive and therapy resistant subpopulations., PMID:40313947
Ophthalmological manifestations and plasma markers of inflammation in Ebola survivors in post-treatment era., PMID:40301432
Ophthalmological manifestations and plasma markers of inflammation in Ebola survivors in post-treatment era., PMID:40301432
"Virtual crossmatch reveals donor-specific MICA antibodies in antibody mediated rejection: First established Indian case"., PMID:40280498
"Virtual crossmatch reveals donor-specific MICA antibodies in antibody mediated rejection: First established Indian case"., PMID:40280498
CLN-619, a MICA/B monoclonal antibody that promotes innate immune cell-mediated antitumor activity., PMID:40274283
CLN-619, a MICA/B monoclonal antibody that promotes innate immune cell-mediated antitumor activity., PMID:40274283
BTK inhibitors enhance NKG2D ligand expression by regulating IL-10/STAT3 pathway in activated non-GCB diffuse large B-cell lymphoma cells., PMID:40029697
BTK inhibitors enhance NKG2D ligand expression by regulating IL-10/STAT3 pathway in activated non-GCB diffuse large B-cell lymphoma cells., PMID:40029697
Frizzled-7-targeting antibody-derived bifunctional protein retargets NK cells against triple-negative breast cancer cells via MICA-NKG2D axis., PMID:40021214
Frizzled-7-targeting antibody-derived bifunctional protein retargets NK cells against triple-negative breast cancer cells via MICA-NKG2D axis., PMID:40021214
An epitope-directed mRNA vaccine inhibits tumor metastasis through the blockade of MICA/B α1/2 shedding., PMID:39999840
An epitope-directed mRNA vaccine inhibits tumor metastasis through the blockade of MICA/B α1/2 shedding., PMID:39999840
Clinico-genomic features predict distinct metastatic phenotypes in cutaneous melanoma., PMID:39975034
Clinico-genomic features predict distinct metastatic phenotypes in cutaneous melanoma., PMID:39975034
Detection and Quantification of Polymorphic MICA and MICB Molecules in Immunoassays: Initial Insights., PMID:39902633
Detection and Quantification of Polymorphic MICA and MICB Molecules in Immunoassays: Initial Insights., PMID:39902633
NTHi killing activity is reduced in COPD patients and is associated with a differential microbiome., PMID:39885466
NTHi killing activity is reduced in COPD patients and is associated with a differential microbiome., PMID:39885466
Role of the androgen receptor in melanoma aggressiveness., PMID:39837817
Evolution of anti-MICA antibodies after imlifidase infusion for a high immunological risk kidney transplantation., PMID:39826255
Evolution of anti-MICA antibodies after imlifidase infusion for a high immunological risk kidney transplantation., PMID:39826255
Novel and potent MICA/B antibody is therapeutically effective in KRAS LKB1 mutant lung cancer models., PMID:39762078
Novel and potent MICA/B antibody is therapeutically effective in KRAS LKB1 mutant lung cancer models., PMID:39762078
Cigarette Smoking and Symptom Burden: Baseline Results From Nine ECOG-ACRIN Cancer Clinical Trials., PMID:39746495
Cigarette Smoking and Symptom Burden: Baseline Results From Nine ECOG-ACRIN Cancer Clinical Trials., PMID:39746495
Circulating cytokine associations with clinical outcomes in melanoma patients treated with combination nivolumab plus ipilimumab., PMID:39699928
Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047., PMID:39671533
Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047., PMID:39671533
[The effect of c-Myc on regulating the immune-related ligands in Y subtype small cell lung cancer through histone deacetylase 1]., PMID:39622733
[The effect of c-Myc on regulating the immune-related ligands in Y subtype small cell lung cancer through histone deacetylase 1]., PMID:39622733
Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients., PMID:39612757
Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients., PMID:39612757
Sequential Vaccination Against Streptococcus pneumoniae Appears as Immunologically Safe in Clinically Stable Kidney Transplant Recipients., PMID:39591147
Sequential Vaccination Against Streptococcus pneumoniae Appears as Immunologically Safe in Clinically Stable Kidney Transplant Recipients., PMID:39591147
MICA and NKG2D gene polymorphisms influence graft survival, and response to therapy in kidney transplantation., PMID:39575256
MICA and NKG2D gene polymorphisms influence graft survival, and response to therapy in kidney transplantation., PMID:39575256
Stratified analysis identifies HIF-2α as a therapeutic target for highly immune-infiltrated melanomas., PMID:39554029
Stratified analysis identifies HIF-2α as a therapeutic target for highly immune-infiltrated melanomas., PMID:39554029
Targeting RAF1 gene fusions with MEK inhibition in metastatic melanoma., PMID:39504576
Targeting RAF1 gene fusions with MEK inhibition in metastatic melanoma., PMID:39504576
Distinct Non-Human Leukocyte Antigen Antibody Signatures Correlate with Endothelial Crossmatch Status in Lung and Renal Transplant Recipients., PMID:39408890
Craters on the melanoma surface facilitate tumor-immune interactions and demonstrate pathologic response to checkpoint blockade in humans., PMID:39345527
Craters on the melanoma surface facilitate tumor-immune interactions and demonstrate pathologic response to checkpoint blockade in humans., PMID:39345527
Bispecific killer cell engagers employing species cross-reactive NKG2D binders redirect human and murine lymphocytes to ErbB2/HER2-positive malignancies., PMID:39267747
Bispecific killer cell engagers employing species cross-reactive NKG2D binders redirect human and murine lymphocytes to ErbB2/HER2-positive malignancies., PMID:39267747
A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors., PMID:39264730
A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors., PMID:39264730
A novel and potent MICA/B antibody is therapeutically effective in KRAS LKB1 mutant lung cancer models., PMID:39211152
A novel and potent MICA/B antibody is therapeutically effective in KRAS LKB1 mutant lung cancer models., PMID:39211152
Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab., PMID:39209453
Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab., PMID:39209453
Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer., PMID:39190534
Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer., PMID:39190534
Isolation of anti-tumor monoclonal antibodies targeting on MICA/B α3 domain by single B cell technology for colon cancer therapy., PMID:39170144
Isolation of anti-tumor monoclonal antibodies targeting on MICA/B α3 domain by single B cell technology for colon cancer therapy., PMID:39170144
Expression and function of the major histocompatibility complex (MHC) class I chain-related A (MICA)*010 in NK cell killing activity., PMID:39116667
Expression and function of the major histocompatibility complex (MHC) class I chain-related A (MICA)*010 in NK cell killing activity., PMID:39116667
Inhibition of MICA and MICB shedding enhances memory-like NK-cell-mediated cytotoxicity against multiple myeloma., PMID:39106432
Inhibition of MICA and MICB shedding enhances memory-like NK-cell-mediated cytotoxicity against multiple myeloma., PMID:39106432
Myocardial Characteristics, Cardiac Structure, and Cardiac Function in Systemic Light-Chain Amyloidosis., PMID:39001736
Myocardial Characteristics, Cardiac Structure, and Cardiac Function in Systemic Light-Chain Amyloidosis., PMID:39001736
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study., PMID:38898592
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study., PMID:38898592
Outcome-based Risk Assessment of Non-HLA Antibodies in Heart Transplantation: A Systematic Review., PMID:38796046
Outcome-based Risk Assessment of Non-HLA Antibodies in Heart Transplantation: A Systematic Review., PMID:38796046
Nanobody-based CAR NK cells for possible immunotherapy of MICA+ tumors., PMID:38756234
Nanobody-based CAR NK cells for possible immunotherapy of MICA+ tumors., PMID:38756234
Chordoma cancer stem cell subpopulation characterization may guide targeted immunotherapy approaches to reduce disease recurrence., PMID:38741774
Chordoma cancer stem cell subpopulation characterization may guide targeted immunotherapy approaches to reduce disease recurrence., PMID:38741774
Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands., PMID:38731936
Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands., PMID:38731936
Transmural Flow Upregulates PD-L1 Expression in Microvascular Networks., PMID:38696611
Transmural Flow Upregulates PD-L1 Expression in Microvascular Networks., PMID:38696611
Evasion of NKG2D-mediated cytotoxic immunity by sarbecoviruses., PMID:38653235
Evasion of NKG2D-mediated cytotoxic immunity by sarbecoviruses., PMID:38653235
Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol., PMID:38630551
Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol., PMID:38630551
Correction: The impact of ageing on the distribution of preformed anti-HLA and anti-MICA antibody specificities in recipients from eastern China prior to initial HSCT., PMID:38615040
Correction: The impact of ageing on the distribution of preformed anti-HLA and anti-MICA antibody specificities in recipients from eastern China prior to initial HSCT., PMID:38615040
A novel MICA/B-targeted chimeric antigen receptor augments the cytotoxicity of NK cells against tumor cells., PMID:38598902
A novel MICA/B-targeted chimeric antigen receptor augments the cytotoxicity of NK cells against tumor cells., PMID:38598902
MICA-specific nanobodies for diagnosis and immunotherapy of MICA+ tumors., PMID:38550583
MICA-specific nanobodies for diagnosis and immunotherapy of MICA+ tumors., PMID:38550583
Synergistic integration of histone deacetylase inhibitors apparently enhances the cytokine-induced killer cell efficiency in multiple myeloma via the NKG2D pathway., PMID:38529413
Synergistic integration of histone deacetylase inhibitors apparently enhances the cytokine-induced killer cell efficiency in multiple myeloma via the NKG2D pathway., PMID:38529413
Order: order@antibodysystem.com
Mail: support@antibodysystem.com
For research use only. Not for human or drug use.
Find out more about placing an order here
